𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A 13-week, multicenter, randomized, double-blind study of lumiracoxib in hip osteoarthritis

✍ Scribed by Thomas J. Schnitzer; I. Dan Dattani; Bruno Seriolo; Hartmut Schneider; Alan Moore; Lillian Tseng; Peter Sallstig; Rosemary Rebuli; Thomas Maxwell


Book ID
106266032
Publisher
Springer
Year
2011
Tongue
English
Weight
521 KB
Volume
30
Category
Article
ISSN
0770-3198

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Efficacy and safety of four doses of lum
✍ Schnitzer, Thomas J. ;Beier, Jannie ;Geusens, Piet ;Hasler, Paul ;Patel, Sanjay πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 128 KB πŸ‘ 3 views

## Abstract ## Objective To compare the efficacy and tolerability of the novel cyclooxygenase 2‐selective inhibitor lumiracoxib with placebo and diclofenac in osteoarthritis (OA). ## Methods Adults (n = 583) with knee or hip OA were randomized to receive for 4 weeks lumiracoxib 50, 100, or 200 m